Amid readouts from the Muscular Dystrophy Association’s annual meeting, the Clinical Trials Arena evaluates five Duchenne trials in 2025.

Charles Schwab Investment Management Inc. reduced its stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 16.3% in the 4th ...

Analysts at Chardan Capital reduced their FY2025 earnings estimates for shares of REGENXBIO in a research report issued to ...

Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.

Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death ...

At the MDA conference, Regenxbio reported interim data from the Phase I/II portion of its Affinity Duchenne study (NCT05693142) that showed RGX-202 was able to induce a 122% microdystrophin ...

Ompenaclid (RGX-202) is in phase 2 testing as a second-line therapy for RAS-mutated advanced or metastatic CRC, a patient population that has seen little in the way of treatment innovation in ...